Monte Rosa Therapeutics, Inc. (GLUE)

Monte Rosa Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	208.34	224.25	128.1	54.91	346.07	41.7
Short-Term Investments	182.92	147.9	104.31	207.91	-	-
Cash & Short-Term Investments	391.26	372.15	232.41	262.83	346.07	41.7
Cash Growth	61.55%	60.12%	-11.57%	-24.05%	729.93%	595.56%
Other Receivables	4.97	0.17	0.51	7.66	-	0.1
Receivables	4.97	0.17	0.51	7.66	-	0.1
Prepaid Expenses	5.59	5.12	3.29	4.44	2.6	1.79
Restricted Cash	-	-	-	0.96	-	-
Total Current Assets	401.82	377.44	236.21	275.89	348.67	43.59
Property, Plant & Equipment	52.66	56.31	62.61	61.91	12.33	4.62
Other Long-Term Assets	5.36	4.98	4.93	4.6	5.34	1.16
Total Assets	459.84	438.73	303.76	342.39	366.33	49.38
Accounts Payable	14.51	17.22	11.15	7.86	6.56	7.07
Accrued Expenses	16.25	15.43	12.93	9.56	9.24	1.13
Current Portion of Leases	4.24	3.71	3.16	3.13	-	-
Current Unearned Revenue	24.79	117.23	17.68	-	-	-
Other Current Liabilities	1.65	3.35	1.67	5.02	0.84	21.08
Total Current Liabilities	61.44	156.95	46.59	25.57	16.64	29.28
Long-Term Leases	35.93	39	42.88	43.87	-	-
Long-Term Unearned Revenue	111.89	16.15	32.32	-	-	-
Pension & Post-Retirement Benefits	4.74	3.7	2.71	1.53	2.18	1.07
Total Liabilities	214	215.8	124.51	70.98	18.81	30.34
Common Stock	0.01	0.01	0.01	0.01	0.01	0
Additional Paid-In Capital	680.16	664.87	547.86	503.7	471.57	0.4
Retained Earnings	-431.08	-438.59	-365.89	-230.54	-122.04	-48.08
Comprehensive Income & Other	-3.25	-3.36	-2.72	-1.75	-2.02	-1.06
Total Common Equity	245.84	222.94	179.25	271.41	347.52	-48.73
Shareholders' Equity	245.84	222.94	179.25	271.41	347.52	19.04
Total Liabilities & Equity	459.84	438.73	303.76	342.39	366.33	49.38
Total Debt	40.17	42.72	46.04	47	-	-
Net Cash (Debt)	351.09	329.43	186.37	215.83	346.07	41.7
Net Cash Growth	76.88%	76.76%	-13.65%	-37.64%	729.93%	695.02%
Net Cash Per Share	4.24	4.46	3.63	4.57	13.84	27.49
Filing Date Shares Outstanding	65.12	61.51	50.14	49.24	46.37	1.69
Total Common Shares Outstanding	61.79	61.51	50.14	49.32	46.54	1.69
Working Capital	340.37	220.49	189.62	250.32	332.03	14.32
Book Value Per Share	3.98	3.62	3.57	5.50	7.47	-28.91
Tangible Book Value	245.84	222.94	179.25	271.41	347.52	-48.73
Tangible Book Value Per Share	3.98	3.62	3.57	5.50	7.47	-28.91
Machinery	29.47	27.4	24.23	18.65	13.06	5.23
Construction In Progress	0.01	0.06	0.92	12.01	0.85	-
Leasehold Improvements	23.64	22.39	20.89	2.66	1.12	-

Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q